CD24 Protein-VLP (AA 27-59)

Catalog No. ABIN7448158

VLP CD24 protein expressed in HEK-293 Cells.

Quick Overview for CD24 Protein-VLP (AA 27-59) (ABIN7448158)

Target: CD24 (CD24 Molecule (CD24))

Protein Type: VLP

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Application: ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details

Protein Characteristics: AA 27-59

Purpose: Human CD24 VLP

Sequence: Ser27-Gly59

Characteristics: Recombinant Human CD24 VLP is expressed from HEK293.It contains Ser27-Gly59 (It may have cross reaction with anti-His antibody).

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1 EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human CD24 VLP at 0.5 ug/ml (100 ul/Well) on the plate. Dose response curve for Anti-CD24 Antibody, hFc Tag with the EC50 of 3.7 ng/ml determined by ELISA (QC Test).

Application Details

Application Notes:

• Antibody Discovery: Immunization, Screening, Functional Characterization
• Affinity determination: ELISA, SPR
• In vivo pharmacokinetic analysis
• CMC method development
• CAR-T Positive Rate Detection
• Blood sample determination: ELISA

Comment:

Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1 mg/mL for 500 μg or 1 mg lyophilized powder. Do not mix by vortex or vigorous shaking.

Buffer: Lyophilized from 0.22 μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C

Storage Comment: -20°C or lower for 12 months as supplied from date of receipt.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: CD24 (CD24 Molecule (CD24))

Alternative Name: CD24

Background: CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

Molecular Weight: 5.0 kDa.

UniProt: P25063

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation